CompletedNot Applicable

TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients

France1,667 participantsStarted 2012-01-01

Plain-language summary

This nationwide observational study emulates a target trial to compare the effect of tocilizumab versus methotrexate initiation on major adverse cardiovascular events (MACE) in patients with incident giant cell arteritis using the French National Health Data System (SNDS).

Who can participate

Age range50 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥50 years Incident hospitalization for giant cell arteritis Initiation of tocilizumab or methotrexate within 6 months Received systemic corticosteroids ≥20 mg/day within 30 days following hospital discharge Exclusion Criteria: * Prior use of tocilizumab or methotrexate Age \>90 years Length of stay \>30 days Not discharged home Prior aortic disease or vascular imaging within 2 years Initiation of both treatments during grace period

What they're measuring

Major Adverse Cardiovascular Events (MACE)

Timeframe: 2 years

Trial details

NCT IDNCT07459335

SponsorGroupe français d'étude des Maladies Inflammatoires de loeil

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Giant Cell Arteritis (GCA) trials